Drug-induced crystal nephropathy: an update

Bibliography

• Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991;1:1061-80
   PubMed Web of Science ®Google Scholar
• Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 1996;11:379-87
   PubMed Web of Science ®Google Scholar
• Conger JD. Acute uric acid nephropathy. Med Clin North Am 1990;74:859-71
   PubMed Web of Science ®Google Scholar
• Perazella MA, Brown E. Electrolyte and acid-base disorders associated with AIDS: an etiologic review. J Gen Intern Med 1994;9:232-6
   PubMed Web of Science ®Google Scholar
• Narins RG, Carley M, Bloom EJ, Harrison DS. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 1990;10:556-64
   PubMed Web of Science ®Google Scholar
• Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982;9:75-83
   PubMed Web of Science ®Google Scholar
• Molina JM, Belenfant X, Doco-Lecompte T, et al. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS 1991;5:587-9
   PubMed Web of Science ®Google Scholar
• Simon DI, Brosius III FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990;150:2379-84
   PubMed Web of Science ®Google Scholar
• Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 1988;12:72-5
   PubMed Web of Science ®Google Scholar
• Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993;39:254-6
   PubMed Web of Science ®Google Scholar
• Sasson JP, Dratch PL, Shortsleeve MJ. Renal US findings in sulfadiazine-induced crystalluria. Radiology 1992;185:739-40
   PubMed Web of Science ®Google Scholar
• de Sequera P, Albalate M, Hernandez J, et al. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. Postgrad Med J 1996;72:557-8
   PubMed Web of Science ®Google Scholar
• Diaz F, Collazos J, Mayo J, Martinez E. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother 1996;30:41-2
   PubMed Web of Science ®Google Scholar
• Buchanan N. Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure. Br Med J 1978;2:172
   PubMedGoogle Scholar
• Lehr DAW. Specific morphology of crystals appearing in the urine administration of sulfanilamide derivatives. Am J Clin Pathol 1942;12:200-9
   Google Scholar
• Keeney RE, Kirk LE, Bridgen D. Acyclovir tolerance in humans. Am J Med 1982;73:176-81
   PubMed Web of Science ®Google Scholar
• Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985;151:362-5
   PubMed Web of Science ®Google Scholar
• Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71
   PubMed Web of Science ®Google Scholar
• Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982;73:182-5
   PubMed Web of Science ®Google Scholar
• Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir. N Engl J Med 1991;325:1178-9
   PubMed Web of Science ®Google Scholar
• Giustina A, Romanelli G, Cimino A, Brunori G. Low-dose acyclovir and acute renal failure. Ann Intern Med 1988;108:312
   PubMedGoogle Scholar
• Dos Santos Mde F, Dos Santos OF, Boim MA, et al. Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. J Am Soc Nephrol 1997;8:361-7
   PubMed Web of Science ®Google Scholar
• Potter JL, Krill CE Jr. Acyclovir crystalluria. Pediatr Infect Dis 1986;5:710-2
   PubMedGoogle Scholar
• Krieble BF, Rudy DW, Glick MR, Clayman MD. Case report: acyclovir neurotoxicity and nephrotoxicity – the role for hemodialysis. Am J Med Sci 1993;305:36-9
   PubMed Web of Science ®Google Scholar
• Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998;50:194-6
   PubMed Web of Science ®Google Scholar
• Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997;349:1294-5
   PubMedGoogle Scholar
• Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997;336:138-40
   PubMed Web of Science ®Google Scholar
• Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25
   PubMed Web of Science ®Google Scholar
• Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:296-7
   PubMedGoogle Scholar
• Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997;30:558-60
   PubMed Web of Science ®Google Scholar
• Grunke M, Valerius T, Manger B, et al. Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir. Clin Infect Dis 1997;25:1270-1
   PubMed Web of Science ®Google Scholar
• Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 1999;161:1765-8
   PubMed Web of Science ®Google Scholar
• Bruce RG, Munch LC, Hoven AD, et al. Urolithiasis associated with the protease inhibitor indinavir. Urology 1997;50:513-8
   PubMed Web of Science ®Google Scholar
• Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001;38:E23
   PubMedGoogle Scholar
• Grases F, Costa-Bauza A, Garcia-Gonzalez R, et al. Indinavir crystallization and urolithiasis. Int Urol Nephrol 1999;31:23-9
   PubMed Web of Science ®Google Scholar
• Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000;34:1414-8
   PubMed Web of Science ®Google Scholar
• White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol 1982;127:593-7
   PubMed Web of Science ®Google Scholar
• Grunberg RW, Silberg SJ. Triamterene-induced nephrolithiasis. JAMA 1981;245:2494-5
   PubMedGoogle Scholar
• Roy LF, Villeneuve JP, Dumont A, et al. Irreversible renal failure associated with triamterene. Am J Nephrol 1991;11:486-8
   PubMed Web of Science ®Google Scholar
• Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985;40:216-8
   PubMedGoogle Scholar
• Farge D, Turner MW, Roy DR, Jothy S. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. Am J Kidney Dis 1986;8:445-9
   PubMed Web of Science ®Google Scholar
• Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982;96:317-20
   PubMed Web of Science ®Google Scholar
• Ettinger B, Oldroyd NO, Sorgel F. Triamterene nephrolithiasis. JAMA 1980;244:2443-5
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989;51:454-61
   PubMedGoogle Scholar
• Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 1986;26:169-73
   PubMed Web of Science ®Google Scholar
• Favre L, Glasson P, Riondel A, Vallotton MB. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci (Lond) 1983;64:407-15
   PubMed Web of Science ®Google Scholar
• Knauf H, Mohrke W, Mutschler E. Delayed elimination of triamterene and its active metabolite in chronic renal failure. Eur J Clin Pharmacol 1983;24:453-6
   PubMed Web of Science ®Google Scholar
• Balis FM, Savitch JL, Bleyer WA, et al. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985;3:485-9
   PubMed Web of Science ®Google Scholar
• Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694-703
   PubMed Web of Science ®Google Scholar
• Perazella MA. Crystal-induced acute renal failure. Am J Med 1999;106:459-65
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15:2125-34
   PubMed Web of Science ®Google Scholar
• Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-16
   PubMed Web of Science ®Google Scholar
• Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot (Tokyo) 1987;40:1081-5
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72
   PubMed Web of Science ®Google Scholar
• Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007;132:2239-52
   PubMed Web of Science ®Google Scholar
• Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61
   PubMedGoogle Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94
   PubMed Web of Science ®Google Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004:CD004094
   Google Scholar
• Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007;22:621-3
   PubMed Web of Science ®Google Scholar
• Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007;49:153-7
   PubMed Web of Science ®Google Scholar
• Andersson H, Bosaeus I. Hyperoxaluria in malabsorptive states. Urol Int 1981;36:1-9
   PubMed Web of Science ®Google Scholar
• Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 1976;70:1096-100
   PubMed Web of Science ®Google Scholar
• Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 2004;66:676-82
   PubMed Web of Science ®Google Scholar
• Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989;32:75-8
   PubMed Web of Science ®Google Scholar
• Connor JP, Curry JM, Selby TL, Perlmutter AD. Acute renal failure secondary to ciprofloxacin use. J Urol 1994;151:975-6
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005;351:31-47
   PubMed Web of Science ®Google Scholar
• Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986;18(Suppl D):187-93
   PubMed Web of Science ®Google Scholar
• Schluter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987;82(suppl):91
   Web of Science ®Google Scholar
• Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986;32:408-17
   PubMed Web of Science ®Google Scholar
• Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995;13:343-58
   PubMed Web of Science ®Google Scholar
• Schacht P, Deck K, Arcieri G. Ciprofloxacin, Product Monograph. Auckland: Adis Press; 1986. p. 59-68
   Google Scholar
• Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988;34:256-60
   PubMed Web of Science ®Google Scholar
• Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000;164:438
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Nadeau K, Cannon CL, Harris HW, Rosen S. Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes. Am J Kidney Dis 1998;31:710-2
   PubMed Web of Science ®Google Scholar
• Sedlacek M, Suriawinata AA, Schoolwerth A, Remillard BD. Ciprofloxacin crystal nephropathy – a ‘new’ cause of acute renal failure. Nephrol Dial Transplant 2006;21:2339-40
   PubMed Web of Science ®Google Scholar
• Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007;50:330-5
   PubMed Web of Science ®Google Scholar
• Montagnac R, Briat C, Schillinger F, et al. Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin. Nephrol Ther 2005;1:44-51
   PubMedGoogle Scholar
• Fogazzi GB, Garigali G, Brambilla C, Daudon M. Ciprofloxacin crystalluria. Nephrol Dial Transplant 2006;21:2982-3
   PubMed Web of Science ®Google Scholar
• Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988;10(Suppl 1):S141-6
   PubMedGoogle Scholar
• Vanner SJ, MacDonald PH, Paterson WG, et al. A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy. Am J Gastroenterol 1990;85:422-7
   PubMed Web of Science ®Google Scholar
• Cohen SM, Wexner SD, Binderow SR, et al. Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis Colon Rectum 1994;37:689-96
   PubMed Web of Science ®Google Scholar
• Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol 2004;19:68-72
   PubMed Web of Science ®Google Scholar
• Tan HL, Liew QY, Loo S, Hawkins R. Severe hyperphosphataemia and associated electrolyte and metabolic derangement following the administration of sodium phosphate for bowel preparation. Anaesthesia 2002;57:478-83
   PubMed Web of Science ®Google Scholar
• Orias M, Mahnensmith RL, Perazella MA. Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol 1999;19:60-3
   PubMed Web of Science ®Google Scholar
• Ahmed M, Raval P, Buganza G. Oral sodium phosphate catharsis and acute renal failure. Am J Gastroenterol 1996;91:1261-2
   PubMed Web of Science ®Google Scholar
• Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003;349:1006-7
   PubMed Web of Science ®Google Scholar
• Ma RC, Chow CC, Yeung VT, et al. Acute renal failure following oral sodium phosphate bowel preparation in diabetes. Diabetes Care 2007;30:182-3
   PubMed Web of Science ®Google Scholar
• Beyea A, Block C, Schned A. Acute phosphate nephropathy following oral sodium phosphate solution to cleanse the bowel for colonoscopy. Am J Kidney Dis 2007;50:151-4
   PubMed Web of Science ®Google Scholar
• Gonlusen G, Akgun H, Ertan A, et al. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006;130:101-6
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005;16:3389-96
   PubMed Web of Science ®Google Scholar
• Khurana AML, Concepcion LA, Nickel LE, Foulks CJ. Acute Phosphate Nephropathy (poster). Prsented at: Renal week, San Diego, CA; 2006
   Google Scholar
• Center for Drug Evaluation and Research, U.S. Food and Drug Administration: Oral Sodium Phosphate Products for Bowel Cleansing. Washington, DC, US. Govt. Printing Office; 2006
   Google Scholar
• Ritskes-Hoitinga J, Mathot JN, Van Zutphen LF, Beynen AC. Inbred strains of rats have differential sensitivity to dietary phosphorus-induced nephrocalcinosis. J Nutr 1992;122:1682-92
   PubMed Web of Science ®Google Scholar
• Wexner SD, Beck DE, Baron TH, et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc 2006;63:894-909
   PubMed Web of Science ®Google Scholar
• Patel V, Emmett M, Santa Ana CA, Fordtran JS. Pathogenesis of nephrocalcinosis after sodium phosphate catharsis to prepare for colonoscopy: intestinal phosphate absorption and its effect on urine mineral and electrolyte excretion. Hum Pathol 2007;38:193-4; author reply 4-5
   PubMed Web of Science ®Google Scholar